Recruiting

Enteral Nutrition

Sponsor:

Andrea Charvet

Code:

NCT06609213

Conditions

Amyotrophic Lateral Sclerosis

Gastrointestinal Intolerance

Enteral Nutrition Therapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Medical Food

Study Details

Brief summary:

The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS. This single arm intervention study all participants will receive the intervention and researchers will utilize validated indicators combined with clinical expertise to assess gastrointestinal symptoms of feeding intolerance before and after the intervention.

The main questions this study aims to answer are:

1. Wil participants meeting a greater percentage of their estimated nutritional needs at baseline present a slower disease progression rate and a lower incidence of GI symptoms of feeding intolerance when feeding via Gtube?
2. Will there be significant change in feeding intolerance when oral intake of enteral nutrition formula precedes feeding via Gtube?

This proposed study consists of three stages, as follows:

1. Pre-Intervention: The lead in period of one-week preceding intervention phase I will be timed to initiate 3 weeks before the scheduled Gtube placement procedure. Patients will be advised to maintain their usual food and beverage intake. Dietary intake and GI symptoms data will be collected by research personnel.
2. Phase I: Dietary intake data collected from the pre-intervention stage will be averaged and used to determine the number of cartons of enteral nutrition formula needed to meet the participants estimated nutritional needs. For two weeks +- 2 days participants will be directed to drink the number of cartons of a pre-selected enteral nutrition formula to meet their estimated nutritional needs when combined to their current oral dietary intake. A plant based EN formula (Kate Farms 1.4 Standard) commonly prescribed for pALS was selected to be provided to all patients in the study to keep this variable constant. Weekly data collection of dietary intake and GI symptoms will be ongoing.
3. Phase II: At the end of phase I, patients will undergo a Gtube placement at their selected medical facility. For the following two weeks +- 2 days participants will be directed to feed via Gtube the same number of cartons of the enteral nutrition formula used orally on phase I and make no changes to their current oral intake.

Conditions

Amyotrophic Lateral Sclerosis

Gastrointestinal Intolerance

Enteral Nutrition Therapy

Study ID

NCT06609213

Start date

Jan 10, 2025

Status verified date

Aug, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of possible, probable, or definite ALS or motor neuron disease by the treating neurologist (El-Escorial Revisited).
  • Planned tube feeding placement within the following 4 to 6 weeks.

Exclusion Criteria:

  • History of Crohns disease, inflammatory bowel disease, irritable bowel syndrome, celiac disease, food allergies and/or sensitivities to any of the formula ingredients, neurodegenerative disease diagnosis outside of ALS, or other concomitant disorder that might contribute to GI symptoms.
  • Diagnosis of frontotemporal dementia.
  • Nil per oral status.
  • Any reason causing the immediate need for a feeding tube placement, including but not limited to severe malnutrition diagnosis.

Study Design

Enrollment

22 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Intervention

This is a single arm study in which all participants receive the intervention.

Interventions

Medical Food

Enteral nutrition formula will be used both by mouth and via feeding tube. This product is considered a medical food.

Primary outcome measure

  • Gastrointestinal Symptoms [ Time Frame: 5 weeks ]

Central Contacts and Locations

Central contacts

Andrea Charvet, PhD, RDN, LDN

954-262-6901acharve1@nova.edu

Locations

Nova Southeastern University, Cathy J, Husman ALS Center

Recruiting

Fort Lauderdale, Florida, United States, 33314

Contacts

Andrea Charvet, Ph.D., RDN, LDN

954-262-6901acharve1@nova.edu

More Information

Sponsor

Andrea Charvet

Last update posted

Aug 4, 2026

Last verified

Aug, 2026

Keywords

  • amyotrophic lateral sclerosis
  • ALS
  • Gtube
  • enteral nutrition
  • feeding intolerance
  • EN intolerance
  • enteral nutrition intolerance
  • gastrointestinal symptoms
  • percutaneous endoscopic gastrostomy
  • PEG

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Andrea Charvet on 2026-08-04.